TerminatedPhase 2

Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)

NCT03297294

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Novartis Investigative Site

Broadmeadow, New South Wales, Australia

+63 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2018-03-14
Enrollment: 142 participants
Sponsor: Novartis Pharmaceuticals
Purpose: treatment

Locations (64)

Novartis Investigative SiteBroadmeadow, New South Wales, Australia
Novartis Investigative SiteOrange, New South Wales, Australia
Novartis Investigative SiteAdelaide, South Australia, Australia
Novartis Investigative SiteHeidelberg Heights, Victoria, Australia
Novartis Investigative SiteGraz, Austria
Novartis Investigative SiteKlagenfurt, Austria
Novartis Investigative SiteVienna, Austria
Novartis Investigative SiteEdegem, Belgium
Novartis Investigative SiteLiège, Belgium
Novartis Investigative SitePellenberg, Belgium
Novartis Investigative SiteSofia, Sofia-Grad, Bulgaria
Novartis Investigative SiteSofia, Bulgaria
Novartis Investigative SiteSofia, Bulgaria
Novartis Investigative SiteSofia, Bulgaria
Novartis Investigative SiteOntario, CAN, Canada
Novartis Investigative SiteThornhill, Ontario, Canada
Novartis Investigative SiteToronto, Ontario, Canada
Novartis Investigative SiteLaval, Quebec, Canada
Novartis Investigative SiteAarhus, Denmark
Novartis Investigative SiteGentofte Municipality, Denmark
Novartis Investigative SiteOdense C, Denmark
Novartis Investigative SiteTampere, Finland
Novartis Investigative SiteBoulogne-Billancourt, France
Novartis Investigative SiteBielefeld, Germany
Novartis Investigative SiteDüsseldorf, Germany
Novartis Investigative SiteEssen, Germany
Novartis Investigative SiteHalle, Germany
Novartis Investigative SiteKassel, Germany
Novartis Investigative SiteKiel, Germany
Novartis Investigative SiteLeipzig, Germany
Novartis Investigative SiteWiesbaden, Germany
Novartis Investigative SiteDebrecen, HUN, Hungary
Novartis Investigative SiteEsztergom, HUN, Hungary
Novartis Investigative SiteSzeged, HUN, Hungary
Novartis Investigative SiteBalatonfüred, Hungary
Novartis Investigative SiteBudapest, Hungary
Novartis Investigative SiteBudapest, Hungary
Novartis Investigative SiteKistarcsa, Hungary
Novartis Investigative SitePécs, Hungary
Novartis Investigative SiteSzeged, Hungary
Novartis Investigative SiteOslo, Norway
Novartis Investigative SiteKrakow, POL, Poland
Novartis Investigative SiteBialystok, Poland
Novartis Investigative SiteWarsaw, Poland
Novartis Investigative SiteCaldas da Rainha, Portugal
Novartis Investigative SiteLisbon, Portugal
Novartis Investigative SiteMatosinhos Municipality, Portugal
Novartis Investigative SitePorto, Portugal
Novartis Investigative SiteViana do Castelo, Portugal
Novartis Investigative SiteVila Nova de Gaia, Portugal
Novartis Investigative SiteLučenec, Slovak Republic, Slovakia
Novartis Investigative SiteBratislava, Slovakia
Novartis Investigative SiteBratislava, Slovakia
Novartis Investigative SitePrešov, Slovakia
Novartis Investigative SitePrešov, Slovakia
Novartis Investigative SiteSeville, Andalusia, Spain
Novartis Investigative SiteMadrid, Spain
Novartis Investigative SiteBradford, West Yorkshire, United Kingdom
Novartis Investigative SiteBath, United Kingdom
Novartis Investigative SiteBournemouth, United Kingdom
Novartis Investigative SiteEdinburgh, United Kingdom
Novartis Investigative SiteLondon, United Kingdom
Novartis Investigative SiteMiddlesbrough, United Kingdom
Novartis Investigative SiteOldham, United Kingdom